EYLEA® delivers long-lasting anti-VEGF activity in the eye, for up to twice as long as ranibizumab1

EYLEA Provides Sustained VEGF Suppression

VEGF, vascular endothelial growth factor.

Reference

  1. Fauser S, Muether PS. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol 2016;100:1494–1498.